He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT). His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells. Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma. He is working on moving this approach from bench to bedside in the form of a Phase 1/2a clinical trial.